Investors

2023

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health plc (AIM: OPTI), announces that it will today be posting a circular to holders of the warrant instruments dated 28 January 2014 and 19 February 2014 (the "Warrant Instruments") comprising notice of two separate general meetings of warrant holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London, EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively (the "Meetings"), and deeds of variation (the "Deeds") for the respective Warrant Instruments.

The Meetings have been convened to propose variations of certain terms of the Warrant Instruments, extending their respective long stop dates from the second anniversary of the date of each Warrant Instrument to the eighth anniversary of the date of each Warrant Instrument. If approved, the new long stop dates for each of the Warrant Instruments would be 28 January 2022 and 19 February 2022 respectively.

Adam Reynolds, a director of the Company, is a holder of the Warrant Instruments and as such the variation of the Deeds will be deemed to be a related party transaction. Pursuant to AIM Rule 13, the directors of the Company, having consulted with its nominated adviser believe the terms to be fair and reasonable as far as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.